LETTER TO THE EDITOR

The improved prognosis of *FLT3*-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data

Authors

Matthew Schwede,[1,2] Gladys Rodriguez,[3] Vanessa E. Kennedy,[4] Solomon Henry,[5] Douglas Wood,[5] Gabriel N. Mannis,[2,6] Ravindra Majeti,[2,6,7] Jonathan H. Chen,[8-10] Eran Bendavid[11,12] and Tian Yi Zhang[2,6]

[1]Department of Oncology, Swedish Cancer Institute, Seattle, WA; [2]Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA; [3]Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; [4]Division of Blood and Marrow Transplant and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA; [5]Technology & Digital Solutions (TDS), Research Technology, and Research Data Services at Stanford Health Care and School of Medicine, Stanford, CA; [6]Cancer Institute, Stanford University School of Medicine, Stanford, CA; [7]Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA; [8]Division of Hospital Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA; [9]Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA; [10]Clinical Excellence Research Center, Stanford University, Stanford, CA; [11]Stanford University, Center for Health Policy, Stanford University School of Medicine, CA and [12]Division of Primary Care and Population Health, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

Correspondence:
T.Y. ZHANG - tzhang8@stanford.edu
E. BENDAVID - ebd@stanford.edu
J. H. CHEN - jonc101@stanford.edu

https://doi.org/10.3324/haematol.2024.286695

Received: September 25, 2024.
Accepted: January 29, 2025.
Early view: February 6, 2025.

©2025 Ferrata Storti Foundation
Published under a CC BY-NC license

Supplementary Table 1: Coefficient of post-midostaurin x *FLT3* ITD interaction term (the DiD term), which reflects the relative change in prognosis of *FLT3* ITD mutations, after adjusting for different variables. Each model below adjusts for the "Baseline model," which is shown in Table 2. In addition to the Baseline model, most regressions here adjust for another variable, such as patient performance status.

Variables adjusted for in model	***HR of DiD term (95% CI)***	***P-value of DiD term***
Baseline model	0.39 (0.22 – 0.68)	0.001
Baseline model + venetoclax	0.39 (0.20 – 0.77)	0.007
Baseline model + performance status	0.34 (0.16 – 0.69)	0.003
Baseline model + log(WBC + 1)	0.40 (0.23 – 0.70)	0.001
Baseline model + FLT3 inhibitor	0.62 (0.30 – 1.3)	0.19